Biogen Idec, Orphan Biovitrum partner for hemophilia B drug trial

Biogen Idec is collaborating with Orphan Biovitrum on a clinical trial to evaluate the safety and efficacy of a recombinant Factor IX Fc fusion protein in preventing bleeding in hemophilia B patients. Biogen Idec also received FDA approval to market Ampyra, a multiple sclerosis drug it owns with Acorda Therapeutics.

View Full Article in:

Mass High Tech (Boston) · Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA